{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:00:07Z","timestamp":1767171607229,"version":"build-2238731810"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma Schweiz AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine.<\/jats:p>\n                    <jats:p>To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An interim analysis was conducted after all patients completed 6\u00a0months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 172 adults with chronic or episodic migraine from 19 different sites across Switzerland were enrolled to receive erenumab every 4\u00a0weeks. At baseline, patients had 16.6\u2009\u00b1\u20097.2 monthly migraine days (MMD) and 11.6\u2009\u00b1\u20097.0 acute migraine-specific medication days per month. After 6\u00a0months, erenumab treatment reduced Headache Impact Test (HIT-6\u2122) scores by 7.7 \u00b1 8.4 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), the modified Migraine Disability Assessment (mMIDAS) by 14.1\u2009\u00b1\u200917.8 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), MMD by 7.6\u2009\u00b1\u20097.0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and acute migraine-specific medication days per month by 6.6 \u00b1 5.4 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Erenumab also reduced the impact of migraine on social and family life, as evidenced by a reduction of Impact of Migraine on Partners and Adolescent Children (IMPAC) scores by 6.1\u2009\u00b1\u20096.7 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients reported a mean effectiveness of 67.1, convenience of 82.4 and global satisfaction of 72.4 in the Treatment Satisfaction Questionnaire for Medication (TSQM-9). In total, 99 adverse events (AE) and 12 serious adverse events (SAE) were observed in 62 and 11 patients, respectively. All SAE were regarded as not related to the study medication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>BASEC ID 2018\u201302,375 in the Register of All Projects in Switzerland (RAPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-022-01515-8","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T07:03:05Z","timestamp":1668754985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results"],"prefix":"10.1186","volume":"23","author":[{"given":"Andreas R.","family":"Gantenbein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reto","family":"Agosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther","family":"Landmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklaus","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele Susanne","family":"Merki-Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ryvlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Schankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Viceic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Arzt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"3","key":"1515_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2040622315579627","volume":"6","author":"MW Weatherall","year":"2015","unstructured":"Weatherall MW (2015) The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 6(3):115\u2013123. https:\/\/doi.org\/10.1177\/2040622315579627","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"1515_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart W, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18(1):101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"key":"1515_CR3","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. (2018). Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"2","key":"1515_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40120-018-0113-0","volume":"7","author":"P Vo","year":"2018","unstructured":"Vo P, Paris N, Bilitou A, Valena T, Fang J, Naujoks C, Cameron A, de Reydet de Vulpillieres F, Cadiou F (2018) Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy\u00a9 Application. Neurol Ther 7(2):321\u2013332. https:\/\/doi.org\/10.1007\/s40120-018-0113-0","journal-title":"Neurol Ther"},{"issue":"1","key":"1515_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","volume":"15","author":"TJ Steiner","year":"2014","unstructured":"Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lant\u00e9ri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barr\u00e9 J, Andr\u00e9e C (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15(1):31. https:\/\/doi.org\/10.1186\/1129-2377-15-31","journal-title":"J Headache Pain"},{"issue":"5","key":"1515_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, Lainez JM, Lampl C, Lant\u00e9ri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andr\u00e9e C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Eur J Neurol"},{"issue":"1","key":"1515_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1129-2377-14-29","volume":"14","author":"E Sokolovic","year":"2013","unstructured":"Sokolovic E, Riederer F, Szucs T, Agosti R, S\u00e1ndor PS (2013) Self-reported headache among the employees of a Swiss university hospital: prevalence, disability, current treatment, and economic impact. J Headache Pain 14(1):29. https:\/\/doi.org\/10.1186\/1129-2377-14-29","journal-title":"J Headache Pain"},{"key":"1515_CR8","unstructured":"Swiss Headache Society (2021). Therapy recommendations, 10.1th edition. https:\/\/headache.ch\/DirectLinks\/Therapieempfehlungen (Last Accessed June 9th, 2022)."},{"issue":"7","key":"1515_CR9","doi-asserted-by":"publisher","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","volume":"10","author":"JL Jackson","year":"2015","unstructured":"Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J (2015) A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS ONE 10(7):e0130733. https:\/\/doi.org\/10.1371\/journal.pone.0130733","journal-title":"PLoS ONE"},{"issue":"1","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 20(1):22\u201333. https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22","journal-title":"J Manag Care Pharm."},{"issue":"1","key":"1515_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C (2016) Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 356(1):223\u2013231. https:\/\/doi.org\/10.1124\/jpet.115.227793","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"1515_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377(22):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"6","key":"1515_CR13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"6","key":"1515_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"8","key":"1515_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Quality Life Res 12(8):963\u2013974. https:\/\/doi.org\/10.1023\/a:1026119331193","journal-title":"Quality Life Res"},{"issue":"3","key":"1515_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1526-4610.2003.03050.x","volume":"43","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Lipton RB, Kolodner K (2003) Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 43(3):258\u2013265. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03050.x","journal-title":"Headache"},{"issue":"4","key":"1515_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/head.13028","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML (2017) Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale. Headache 57(4):570\u2013585. https:\/\/doi.org\/10.1111\/head.13028","journal-title":"Headache"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E (2009) Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 7:36. https:\/\/doi.org\/10.1186\/1477-7525-7-36 Those seeking information regarding or permission to use the TSQM are directed to IQVIA at. https:\/\/www.iqvia.com\/TSQM or https:\/\/TSQM@iqvia.com","journal-title":"Health Qual Life Outcomes"},{"key":"1515_CR19","unstructured":"Product information Aimovig, www.swissmedicinfo.ch (Last Accessed June 9th, 2022)."},{"issue":"2","key":"1515_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40122-021-00331-3","volume":"10","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Lucas C, Watson D, Gaul C, Ramsden E, Ritter S, Martelletti P, Snellman J (2021) Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. Pain Ther 10(2):1691\u20131708. https:\/\/doi.org\/10.1007\/s40122-021-00331-3","journal-title":"Pain Ther"},{"issue":"4","key":"1515_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jclinepi.2005.05.010","volume":"59","author":"RR Coeytaux","year":"2006","unstructured":"Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF (2006) Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol 59(4):374\u2013380. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.05.010","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"1515_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D\u2019Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group (2021) Long-term (48\u00a0weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 61(9):1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache"},{"issue":"1","key":"1515_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102420973994","volume":"41","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD (2021) Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia 41(1):6\u201316. https:\/\/doi.org\/10.1177\/0333102420973994","journal-title":"Cephalalgia"}],"updated-by":[{"DOI":"10.1186\/s10194-022-01530-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01515-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:05:43Z","timestamp":1671437143000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01515-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01515-8","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-022-01530-9","URL":"https:\/\/doi.org\/10.1186\/s10194-022-01530-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SQUARE study was approved by the competent lead ethics committee (Ethikkommission Nordwest- und Zentralschweiz EKNZ) in February 2019 and can therefore be found under BASEC ID 2018\u201302375 in the Register of All Projects in Switzerland (RAPS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: ARG reports honorarium and\/or consulting fees from Allergan, Almirall, Amgen, Curatis, Eli Lilly, Gr\u00fcnenthal, Lundbeck, Novartis and TEVA Pharmaceuticals. RA report honoraria for speaker, advisory board and\/or investigator activities from Allergan, Almogran, Drossa Pharma, Eli Lilly, Lundbeck, Medical Tribune (Biomed, Schwabe), Merz, Novartis and TEVA. CPK has received honoraria for lectures as well as research support from Almirall, Biogen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, Swiss MS Society (SMSG) and Teva. GL reports honorarium and\/or consulting fees from Almirall, Eli Lilly, Gr\u00fcnenthal, Novartis and Pfizer. NM reports honorarium for his participation to an advisory board from Novartis. GSM reports honoraria for advisor and speaker activities from Novartis. HP received honoraria from Eli Lilly, speaker fees from Novartis and TEVA Pharmaceuticals as well as fundings from the Werner Dessauer Stiftung. PR's institution has received fees for his participation to advisory boards or speaker fees from Eli-Lilly, Lundbeck Novartis, and Teva pharmaceuticals. CJS received consulting, advisory boards and speaker fees as well as travel support from Allergan, Almirall, Amgen, Eli Lilly, Gr\u00fcnenthal, Lundbeck, MindMed, Novartis, TEVA Pharmaceuticals; part-time-employee at Zynnon, and has received funding from Baasch-Medicus Foundation Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft (\n                      \n                      ) and Swiss Heart Foundation outside the submitted work. JAP declared no conflict of interests. DV received financial support for consultancies and research from Eli Lilly, Novartis and Teva Pharma. CZ has received honoraria for advisory boards from the Swiss MS Society. Ente Ospedaliero Cantonale (employer) received compensation for C.Z.\u2019s speaking activities, consulting fees, or research grants from Almirall, Biogen Idec, Bristol Meyer Squibb, Lundbeck, Merck, Novartis, Sanofi, Teva Pharma, Roche. CZ is recipient of a grant for senior reseachers provided by AFRI (Area Formazione accademica, Ricerca ed Innovazione). ES, IM, and MEA are employees of Novartis Pharma Schweiz AG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}